LEADER 01516nam0 2200385 i 450 001 SUN0123645 005 20200319012322.663 010 $d0.00 017 70$2N$a9783319438665 100 $a20190926d2017 |0engc50 ba 101 $aeng 102 $aCH 105 $a|||| ||||| 200 1 $a*XAFS Techniques for Catalysts, Nanomaterials, and Surfaces$fYasuhiro Iwasawa, Kiyotaka Asakura, Mizuki Tada editors 205 $aCham : Springer, 2017 210 $aIX$d556 p.$cill. ; 24 cm 215 $aPubblicazione in formato elettronico 620 $aCH$dCham$3SUNL001889 676 $a530.417$cFisica superficiale$v22 676 $a540$cChimica generale$v22 676 $a543.54$cSpettroscopia molecolare$v22 676 $a502.82$cMicroscopia$v22 676 $a620.5$cNanotecnologia$v22 676 $a541.395$cCatalisi$v22 676 $a530.4175$cFilm sottili$v22 702 1$aIwasawa$b, Yasuhiro$3SUNV095109 702 1$aAsakura$b, Kiyotaka$3SUNV095110 702 1$aTada$b, Mizuki$3SUNV095111 712 $aSpringer$3SUNV000178$4650 801 $aIT$bSOL$c20200921$gRICA 856 4 $uhttps://link.springer.com/book/10.1007%2F978-3-319-43866-5#toc 912 $aSUN0123645 950 $aUFFICIO DI BIBLIOTECA DEL DIPARTIMENTO DI SCIENZE E TECNOLOGIE AMBIENTALI BIOLOGICHE E FARMACEUTICHE$d17CONS e-book 2111 $e17BIB2111 156 20190926 996 $aXAFS Techniques for Catalysts, Nanomaterials, and Surfaces$91561792 997 $aUNICAMPANIA LEADER 01005nam0 22002411i 450 001 UON00182905 005 20231205103140.79 010 $a88-7673-015-X 100 $a20030730d1984 |0itac50 ba 101 $aita 102 $aIT 105 $a|||| 1|||| 200 1 $aTribunale della libertà$eil procedimento di riesame dei provvedimenti restritt ivi dalla teoria alla pratica$fAntonio Bevere 210 $aRoma$cSapere 2000$d1984 - 11 1 p. ; 21 cm 410 1$1001UON00171720$12001 $aCritica del diritto. Quaderni $1210 $aRoma$cSapere 2000$v4 606 $aDiritto penale$xLeggi speciali$3UONC037846$2FI 700 1$aBEVERE$bAntonio$3UONV105578$00 801 $aIT$bSOL$c20250221$gRICA 899 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$2UONSI 912 $aUON00182905 950 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$dSI PEN B 0262 $eSI SC 23359 5 0262 996 $aTribunale della libertà$9818081 997 $aUNIOR LEADER 02526nam 2200589 a 450 001 9910969216603321 005 20200520144314.0 010 $a9781608052974 010 $a1608052974 035 $a(CKB)2670000000148694 035 $a(EBL)864207 035 $a(OCoLC)779141401 035 $a(SSID)ssj0000942934 035 $a(PQKBManifestationID)11492225 035 $a(PQKBTitleCode)TC0000942934 035 $a(PQKBWorkID)10976890 035 $a(PQKB)11670260 035 $a(OCoLC)785783102 035 $a(MiAaPQ)EBC864207 035 $a(DE-B1597)731336 035 $a(DE-B1597)9781608052974 035 $a(EXLCZ)992670000000148694 100 $a20120315d2012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aMultiple myeloma $ea new era of treatment strategies /$feditors, Klaus Podar, Kenneth C. Anderson 205 $a1st ed. 210 $a[U.S.A.] $cBentham Science Publishers$d[2012] 215 $a1 online resource (217 p.) 300 $aDescription based upon print version of record. 311 08$a9781608056095 311 08$a1608056090 320 $aIncludes bibliographical references and index. 327 $asection 1. Multiple myeloma -- section 2. Treatment guidelines -- section 3. The bone marrow microenvironment and the pathogenesis of multiple myeloma -- section 4. New treatment strategies. 330 $aMultiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced disruption of the bone marrow homeostasis between the highly organized cellular and extracellular compartments supports MM cell proliferation, survival, migration, and drug resistance via activation of various signaling pathways. Based on this knowledge, the prototypic drugs thalidomide, bortezomib, and lenalidomide, which target both MM cell 606 $aMultiple myeloma$xTreatment 615 0$aMultiple myeloma$xTreatment. 676 $a616.99/418 676 $a616.99418 700 $aPodar$b Klaus, $4aut$4http://id.loc.gov/vocabulary/relators/aut$01800395 701 $aPodar$b Klaus$01800395 701 $aAnderson$b Kenneth C$0876632 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910969216603321 996 $aMultiple myeloma$94345157 997 $aUNINA